hexamethonium has been researched along with Nervous System Diseases in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Marin, P | 1 |
Maus, M | 1 |
Desagher, S | 1 |
Glowinski, J | 1 |
Prémont, J | 1 |
1 other study available for hexamethonium and Nervous System Diseases
Article | Year |
---|---|
Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity.
Topics: Acetylcholine; Animals; Carbachol; Cells, Cultured; Dimethylphenylpiperazinium Iodide; Hexamethonium | 1994 |